Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARVAC-CG Booster Vaccine Study
NCT05752201Phase 3Completed
- Sponsor
- CEMIC
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ARVAC-CG in coronavirus disease 2019 (COVID-19), sponsored by CEMIC. Started Feb 2023; status: completed.
02
Drugs
ARVAC-CG
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05752201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752201.